share_log

EyePoint Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC ·  Feb 3 05:26
Summary by Futu AI
EyePoint Pharmaceuticals officer David S. Jones is set to sell 10,104 shares of common stock on 02/02/2024, as per the latest filing. These shares, valued at an aggregate market value of $288,065.04, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This sale follows a series of transactions over the past three months where a total of 72,983 shares were sold, amounting to gross proceeds of $1,753,183.17.
EyePoint Pharmaceuticals officer David S. Jones is set to sell 10,104 shares of common stock on 02/02/2024, as per the latest filing. These shares, valued at an aggregate market value of $288,065.04, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This sale follows a series of transactions over the past three months where a total of 72,983 shares were sold, amounting to gross proceeds of $1,753,183.17.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.